How Technology is Reshaping the Rare Disease Landscape
PRA has recently released a white paper about technology’s effects on rare disease research.
Approximately 7,000 rare diseases affect an estimated 350 million people worldwide, and with diagnostic advances, new diseases are discovered every day. Although the number of clinical trials in rare diseases has increased by 56% in the last 3 years, only 5% of rare diseases have a US Food and Drug Administration (FDA)-approved treatment.
Drug developers can use technology to power this new model and increase access to clinical trials; it allows them to bring new therapies to rare disease patients faster.
Advanced technology fosters these advancements by:
• Identifying patients globally using digital outreach and awareness campaigns
• Decreasing the burden of participation for patients and increasing retention using
connected mobile devices
• Expediting research through real-time, device-based data collection
• Improving study compliance and data quality
Although transitioning from a traditional site-centric paradigm to a patient-focused connected trial model may seem daunting, this white paper provides practical strategies for easing the participation burden and introduces considerations for selecting technology that can seamlessly integrate clinical trials into patients’ lives.
Much more is covered in the document. Download the white paper now.